Vortex Biosciences Announces Publication in Oncotarget That Demonstrates the Value of Combining CTCs and cfDNA in Assessing Cancer Patient Disease

Share Article

Mutation profiles from matched tumor and blood samples were compared between the tumor, cfDNA and CTCs.

Our next generation CTC capture system allow for the collection of CTCs after the plasma has been removed for cfDNA extraction in a simple, easy to use workflow.

Vortex Biosciences, provider of circulating tumor cell (CTC) capture systems, today announced the publication of “Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer” in Oncotarget on November 15th, 2016. The peer reviewed publication describes the use of Vortex technology to capture CTCs and compare mutation profiles in the CTC DNA, cfDNA, and tumor biopsy DNA. There were several examples where CTCs exhibited a mutation that was not detected in ctDNA, and vice versa. Complementary assessment of both CTCs and ctDNA appears advantageous to assess dynamic tumor profiles.

From 15 patients with advanced CRC undergoing liver metastasectomy with curative intent, 41 blood samples were collected at different time points before and after liver surgery for CTC-isolation and quantification using the Vortex technology. The Vortex Bioscience technology captures unlabeled CTCs in whole blood by trapping the cells in microscale vortices while smaller red and white blood cells pass through. After selective trapping of the CTCs in microfluidic chambers, CTCs are flushed and collected into a variety of containers for downstream analysis. In this publication, KRAS, BRAF, and PIK3CA hotspot mutations were analyzed in CTCs and cfDNA from 23 samples, 9 matched liver metastases and 3 primary tumor samples.

"We see CTCs and cfDNA as complimentary to each other, together offering a better understanding of a patient’s disease," said Gene Walther, Chief Executive Officer of Vortex Biosciences. "Our next generation CTC capture system allow for the collection of CTCs after the plasma has been removed for cfDNA extraction in a simple, easy to use workflow.“

80% of patient blood samples were positive for CTCs, using a healthy baseline value as a threshold. This includes 19% of patients that were EpCAM negative and thus would not have been identified by CTC enrichment technologies targeting EpCAM. Among 23 matched CTC and cfDNA samples, we found a concordance of 78.2% for KRAS, 73.9% for BRAF and 91.3% for PIK3CA mutations. The concordance with the tumor samples for CTCs and ctDNA respectively was 72% and 76%. However, when the mutation profile detected in CTCs and cfDNA was combined, the concordance with the tumor was >95%.

With the ability to capture both CTCs and cfDNA in a simple workflow, the Vortex technology can seamlessly integrate into a genomic testing process, transforming the way patient samples can be analyzed.

About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company that integrates cancer biology, microfluidic engineering and informatics to develop tools for isolating and characterizing circulating tumor cells. The Vortex technology enables the harvesting of intact circulating tumor cells from whole blood samples for use in downstream research and clinical applications such as patient stratification in clinical trials, monitoring disease progression and drug treatment effectiveness. With a mission to enable noninvasive diagnosis of cancer and real-time monitoring throughout a patient’s treatment, Vortex is at the forefront of accelerating cancer research and improving patient outcomes. Vortex is a core subsidiary of NetScientific plc, a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercializing technologies that significantly improve the health and well-being of people with chronic diseases. For more information, visit http://www.vortexbiosciences.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Steve Crouse
Visit website